Prostate News and Research

RSS

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.

30 Apr 2010

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

FDA approves new treatment option for prostate cancer

Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration.

30 Apr 2010

IRIC launches new RNA engineering laboratory in Canada

The Institute for Research in Immunology and Cancer of the Universit- de Montr-al is proud to announce the launch of the very first ribonucleic acid engineering laboratory in Canada.

30 Apr 2010

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

30 Apr 2010

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

Bavarian Nordic A/S announced today that PROSTVAC™ has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for its proposed use in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

29 Apr 2010

Realton closes Series B financing

Realton Corporation, a pioneer in developing diode-pumped laser systems initially targeted to treat enlarged prostate, today announced the closing of its Series B financing co-led by OrbiMed Advisors and China Healthcare Partnership. Existing investor CSV Capital Partners will also participate in the financing. The financing will be used primarily to enhance Realton's marketing and distribution networks, expand its manufacturing capabilities and pursue new technology development.

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month.

28 Apr 2010

Cancer-related expenditures increase faster than any other area of health care: JAMA

From 1999 through 2006 the use of diagnostic imaging for Medicare patients with cancer increased, with use of positron emission tomography increasing the most significantly, according to a study in the April 28 issue of JAMA. Imaging costs for these patients also increased, outpacing the rate of increase in total costs among Medicare beneficiaries with cancer.

28 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Usually when all else fails with a technical device, a "reset" button can be pressed, preventing a glitch from going any further. What if that could be done with threats to a person's health? Investigators from The Cancer Institute of New Jersey and the Environmental & Occupational Health Sciences Institute which is jointly administered by UMDNJ-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey, have discovered that a form of a dietary trace element known as selenium can help reset a cell's "biological clock" when it is disrupted by a chemical cancer-causing agent (carcinogen).

28 Apr 2010

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.

28 Apr 2010

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

Researchers from Case Western Reserve University School of Dental Medicine and University Hospitals Case Medical Center report initial results from a small sample that inflammation from gum disease and prostate problems just might be linked. They discuss their new evidence in the Journal of Periodontology, the official journal of the American Academy of Periodontology.

27 Apr 2010

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics.

26 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Personal risk of developing prostate cancer increases when more direct relatives are affected

For a long time now doctors have known that prostate cancer "runs in the family". Men with family members who have been diagnosed with the disease have an elevated risk of developing cancer of the prostate. But exactly how high is an individual person's risk? For whom and at what age should an early detection screening urgently be recommended?

24 Apr 2010

Prostate News and Research

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

PROVENGE receives FDA approval for treatment of CRPC

FDA approves new treatment option for prostate cancer

IRIC launches new RNA engineering laboratory in Canada

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

FDA approves Provenge prostate cancer vaccine

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

Realton closes Series B financing

A new approach for treating neurological and degenerative disorders

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Cancer-related expenditures increase faster than any other area of health care: JAMA

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Personal risk of developing prostate cancer increases when more direct relatives are affected

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News